Predictive Oncology (POAI) announced that it has completed the sale of assets related to its wholly owned subsidiary, Skyline Medical, to DeRoyal Industries. As previously disclosed, Skyline Medical’s business operated outside the core focus of Predictive Oncology, which is the use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients. This transaction was consummated in anticipation of Predictive Oncology’s previously announced merger with Renovaro Biosciences.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on POAI:
- Renovaro completes first milestone payment for Predictive Oncology deal
- Predictive Oncology moves to finalize merger agreement with Renovaro
- Predictive Oncology prices 363,336 shares at $1.50 in registered direct offering
- Predictive Oncology reports positive results using AI for drug repurposing
- Predictive partners with Tecan Group for high-throughput drug screening